Cole Pinnow's most recent trade in Cogent Biosciences Inc was a trade of 240,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 23, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 7.60 per share. | 14 Jan 2025 | 43,750 | 45,848 (0%) | 0% | 7.6 | 332,413 | Common Stock |
Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) |